Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report released on Friday, AnalystRatings.com reports. They currently have a $9.00 target price on the stock.
Several other research analysts have also commented on the stock. ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Mizuho reaffirmed a “buy” rating and issued a $4.00 price target on shares of Selecta Biosciences in a report on Sunday, August 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $6.00 price target on shares of Selecta Biosciences in a report on Friday. Finally, Zacks Investment Research lowered shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, October 10th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $6.67.
Shares of SELB traded down $0.15 during midday trading on Friday, hitting $1.39. The company had a trading volume of 15,694 shares, compared to its average volume of 161,167. The company’s 50 day moving average price is $1.61 and its 200 day moving average price is $1.88. The stock has a market cap of $70.76 million, a price-to-earnings ratio of -0.48 and a beta of 1.11. Selecta Biosciences has a 52 week low of $1.28 and a 52 week high of $6.33.
Selecta Biosciences (NASDAQ:SELB) last released its earnings results on Thursday, August 8th. The company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.07). The firm had revenue of $0.01 million for the quarter. On average, research analysts predict that Selecta Biosciences will post -1.2 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Nationwide Fund Advisors boosted its holdings in shares of Selecta Biosciences by 224.5% in the 2nd quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock valued at $131,000 after buying an additional 4,561 shares during the period. Rhumbline Advisers boosted its stake in Selecta Biosciences by 43.7% during the 2nd quarter. Rhumbline Advisers now owns 16,792 shares of the company’s stock valued at $222,000 after purchasing an additional 5,103 shares during the period. Alps Advisors Inc. boosted its stake in Selecta Biosciences by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 29,958 shares of the company’s stock valued at $305,000 after purchasing an additional 5,207 shares during the period. Barclays PLC boosted its stake in Selecta Biosciences by 87.6% during the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock valued at $34,000 after purchasing an additional 5,911 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Selecta Biosciences by 1.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 365,138 shares of the company’s stock valued at $7,131,000 after purchasing an additional 6,292 shares during the period. 46.44% of the stock is owned by institutional investors and hedge funds.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Read More: What is a dead cat bounce?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.